---
title: "VSee Health | 10-Q: FY2025 Q2 Revenue: USD 3.39 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261323800.md"
published_at: "2025-10-15T21:32:35.000Z"
---

# VSee Health | 10-Q: FY2025 Q2 Revenue: USD 3.39 M

Revenue: As of FY2025 Q2, the actual value is USD 3.39 M.

EPS: As of FY2025 Q2, the actual value is USD -0.16.

EBIT: As of FY2025 Q2, the actual value is USD -2.014 M.

### Segment Revenue

-   **Technology Segment**: Revenue for the six months ended June 30, 2025, was $4,458,800, compared to $3,269,992 for the same period in 2024, representing an increase of $1,188,808 or 36%.
-   **Telehealth Segment**: Revenue for the six months ended June 30, 2025, was $2,252,805, compared to $62,569 for the same period in 2024, representing an increase of $2,190,236 or 3,501%.

### Operational Metrics

-   **Gross Margin**: For the six months ended June 30, 2025, the Technology segment reported a gross margin of $2,023,181, while the Telehealth segment reported a gross margin of $1,425,282.
-   **Operating Income (Loss)**: The Technology segment reported an operating loss of - $83,969 for the six months ended June 30, 2025, while the Telehealth segment reported an operating loss of - $1,300,001.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was - $765,094, compared to - $2,594,214 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: For the six months ended June 30, 2025, net cash used in investing activities was - $15,466, compared to - $16,390 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $746,040, compared to $3,597,841 for the same period in 2024.

### Unique Metrics

-   **Amortization Expense**: For the six months ended June 30, 2025, the Company recorded amortization expense of $1,149,998 within general and administrative expenses.

### Future Outlook and Strategy

-   **Core Business Focus**: The Company plans to leverage its industry relationships with government, hospital systems, and insurance providers to increase its customer base and expand within the telehealth market.
-   **Non-Core Business**: The Company is exploring additional financing options to support its working capital needs and fund growth initiatives.

### Priority

-   The Company emphasizes strategies with concrete projections, such as expanding its telehealth offerings and leveraging its scalable technology platform to meet the unique needs of the healthcare industry.

### Related Stocks

- [VSEE.US - VSee Health](https://longbridge.com/en/quote/VSEE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 独家报道：便士股 VSee Health 与 GoMyRx 合作，扩展远程医疗药物配送服务 | VSEE Health Inc. 与 GoMyRx 合作，通过整合处方履行和药物配送来增强远程医疗服务。此次战略合作旨在改善美国的数字医疗服务交付。GoMyRx 将作为 VSEE 的主要运营合作伙伴，促进处方工作流程和直接面向患者的服务。该 | [Link](https://longbridge.com/en/news/274981770.md) |
| VSee Health 在在线研讨会上展示了适用于农村医院的移动 ICU 解决方案 | VSee Health Inc. 将于 2026 年 2 月 4 日举办一场题为 “按需 ICU：可持续的农村医疗保健” 的在线研讨会。此次活动将讨论按需 ICU、远程 ICU 和移动 ICU 模型如何在不需要新单元或额外专家的情况下增强农 | [Link](https://longbridge.com/en/news/274164982.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.